查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1738367

下一代生物治疗市场－全球产业规模、份额、趋势、机会及预测，按治疗领域、技术、地区及竞争情况细分，2020-2030 年

Next Generation Biotherapeutics Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Therapeutic Area, By Technology, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024年，全球新一代生物治疗药物 (NGBT) 市场规模达54.2亿美元，预计2030年将达到107.5亿美元，复合年增长率达12.05%。 NGBT标誌着生物製药创新的一次变革性飞跃，利用基因治疗、细胞治疗、RNA干扰和单株抗体等先进技术，提供精准的个人化治疗。这些疗法旨在针对特定的疾病机制，提高疗效的同时最大限度地减少副作用。它们适用于各种疾病，为对传统疗法无效的患者带来了新的希望。随着对客製化、数据驱动型医疗解决方案的需求日益增长，NGBT正在全球医疗体系中迅速普及。透过激活人体的自然机制并利用下一代分子策略，这些生物疗法正在重塑医疗模式。随着研发的不断突破，NGBT 正在提高治疗复杂且以前无法治疗的疾病的可能性，提供更好的临床结果并重新定义患者护理的标准。

市场概览
预测期 2026-2030
2024年市场规模 54.2亿美元
2030年市场规模 107.5亿美元
2025-2030 年复合年增长率 12.05%
成长最快的领域 肿瘤学
最大的市场 北美洲

关键市场驱动因素

癌症发生率上升

主要市场趋势

人口老化加剧

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：下一代生物治疗市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依治疗领域（肿瘤学、自体免疫/发炎性疾病）
    • 依技术（抗体药物偶联物、双特异性抗体、抗体片段、抗体样蛋白、其他）
    • 按地区
    • 按公司分类（2024）
  • 市场地图

第六章：北美下一代生物治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第七章：欧洲下一代生物治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙

第八章：亚太下一代生物治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：南美洲下一代生物治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲下一代生物治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章：市场动态

  • 驱动程式
  • 挑战

第 12 章：市场趋势与发展

  • 最新动态
  • 产品发布
  • 併购

第 13 章：全球下一代生物治疗市场：SWOT 分析

第 14 章：竞争格局

  • Xencor, Inc.
  • Regenxbio & Neurimmune AG
  • Takeda Pharmaceutical Company Limited
  • Pfizer, Inc.
  • AstraZeneca Plc.
  • F. Hoffmann-La Roche Ltd.
  • Kyowa Kirin Co., Ltd
  • Seattle Genetics, Inc
  • ImmunoGen, Inc
  • Ono Pharmaceuticals Co, Ltd

第 15 章：策略建议

第16章调查会社について・免责事项

简介目录
Product Code: 8069

The Global Next Generation Biotherapeutics (NGBT) Market was valued at USD 5.42 billion in 2024 and is projected to reach USD 10.75 billion by 2030, growing at a CAGR of 12.05%. NGBTs signify a transformative leap in biopharmaceutical innovation, utilizing advanced technologies such as gene therapy, cell therapy, RNA interference, and monoclonal antibodies to deliver precise and personalized treatment. These therapies are engineered to target specific disease mechanisms, improving treatment effectiveness while minimizing adverse effects. Their application spans a wide range of conditions, offering new hope for patients unresponsive to conventional therapies. As the demand for tailored, data-driven healthcare solutions grows, NGBTs are rapidly gaining traction across global healthcare systems. By activating the body's natural mechanisms and harnessing next-gen molecular strategies, these biotherapeutics are reshaping medical treatment paradigms. With continuous R&D breakthroughs, NGBTs are advancing the possibilities of treating complex and previously untreatable diseases, offering better clinical outcomes and redefining standards in patient care.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 5.42 Billion
Market Size 2030USD 10.75 Billion
CAGR 2025-203012.05%
Fastest Growing SegmentOncology
Largest MarketNorth America

Key Market Drivers

Increasing Incidence of Cancer

The escalating global cancer burden is a major factor propelling the demand for Next Generation Biotherapeutics. Cancer rates are expected to rise by 77% by 2050 compared to 2022, highlighting an urgent need for more precise, effective treatment strategies. Traditional treatments like chemotherapy and radiation are often associated with systemic toxicity and limited efficacy. In contrast, NGBT harnesses advanced genomic profiling to tailor therapies to an individual's unique genetic profile, targeting cancer at its molecular root. These therapies are designed to overcome resistance mechanisms and minimize damage to healthy tissues, enhancing therapeutic precision and patient quality of life. As the need for more adaptable and less invasive therapies intensifies, NGBTs are positioned as a vital component in the evolving landscape of oncology treatment.

Key Market Trends

Increasing Aging Population

The global demographic shift toward an older population is a major trend fueling demand for NGBTs. By 2050, the population aged 65 and above is expected to grow to 16%, further increasing to 24% by 2100. With age comes a heightened prevalence of chronic and degenerative diseases such as cancer, cardiovascular disorders, and neurodegenerative conditions. NGBTs provide targeted, innovative therapies tailored to the complex health needs of aging individuals. These biotherapeutics offer a high level of personalization, which is especially critical for elderly patients managing multiple comorbidities. Their potential to reduce hospitalizations and long-term care needs also makes them attractive for healthcare systems aiming to improve outcomes while controlling costs. As aging continues to drive global healthcare demand, NGBTs stand out as a promising solution for personalized, effective disease management in elderly populations.

Key Market Players

  • Xencor, Inc.
  • Regenxbio & Neurimmune AG
  • Takeda Pharmaceutical Company Limited
  • Pfizer, Inc.
  • AstraZeneca Plc.
  • F. Hoffmann-La Roche Ltd.
  • Kyowa Kirin Co., Ltd
  • Seattle Genetics, Inc
  • ImmunoGen, Inc
  • Ono Pharmaceuticals Co, Ltd

Report Scope:

In this report, the Global Next Generation Biotherapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Next Generation Biotherapeutics Market, By Therapeutic Area:

  • Oncology
  • Autoimmune/ Inflammatory Diseases

Next Generation Biotherapeutics Market, By Technology:

  • Antibody-Drug Conjugates
  • Bispecific Antibodies
  • Antibody Fragments
  • Antibody-like Proteins
  • Others

Next Generation Biotherapeutics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Next Generation Biotherapeutics Market.

Available Customizations:

Global Next Generation Biotherapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Next Generation Biotherapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapeutic Area (Oncology, Autoimmune/ Inflammatory Diseases)
    • 5.2.2. By Technology (Antibody-Drug Conjugates, Bispecific Antibodies, Antibody Fragments, Antibody-like Proteins, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Next Generation Biotherapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapeutic Area
    • 6.2.2. By Technology
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Next Generation Biotherapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Therapeutic Area
        • 6.3.1.2.2. By Technology
    • 6.3.2. Canada Next Generation Biotherapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Therapeutic Area
        • 6.3.2.2.2. By Technology
    • 6.3.3. Mexico Next Generation Biotherapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Therapeutic Area
        • 6.3.3.2.2. By Technology

7. Europe Next Generation Biotherapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapeutic Area
    • 7.2.2. By Technology
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Next Generation Biotherapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapeutic Area
        • 7.3.1.2.2. By Technology
    • 7.3.2. United Kingdom Next Generation Biotherapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapeutic Area
        • 7.3.2.2.2. By Technology
    • 7.3.3. Italy Next Generation Biotherapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapeutic Area
        • 7.3.3.2.2. By Technology
    • 7.3.4. France Next Generation Biotherapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Therapeutic Area
        • 7.3.4.2.2. By Technology
    • 7.3.5. Spain Next Generation Biotherapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Therapeutic Area
        • 7.3.5.2.2. By Technology

8. Asia-Pacific Next Generation Biotherapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapeutic Area
    • 8.2.2. By Technology
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Next Generation Biotherapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapeutic Area
        • 8.3.1.2.2. By Technology
    • 8.3.2. India Next Generation Biotherapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapeutic Area
        • 8.3.2.2.2. By Technology
    • 8.3.3. Japan Next Generation Biotherapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapeutic Area
        • 8.3.3.2.2. By Technology
    • 8.3.4. South Korea Next Generation Biotherapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapeutic Area
        • 8.3.4.2.2. By Technology
    • 8.3.5. Australia Next Generation Biotherapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapeutic Area
        • 8.3.5.2.2. By Technology

9. South America Next Generation Biotherapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapeutic Area
    • 9.2.2. By Technology
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Next Generation Biotherapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapeutic Area
        • 9.3.1.2.2. By Technology
    • 9.3.2. Argentina Next Generation Biotherapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapeutic Area
        • 9.3.2.2.2. By Technology
    • 9.3.3. Colombia Next Generation Biotherapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapeutic Area
        • 9.3.3.2.2. By Technology

10. Middle East and Africa Next Generation Biotherapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapeutic Area
    • 10.2.2. By Technology
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Next Generation Biotherapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapeutic Area
        • 10.3.1.2.2. By Technology
    • 10.3.2. Saudi Arabia Next Generation Biotherapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapeutic Area
        • 10.3.2.2.2. By Technology
    • 10.3.3. UAE Next Generation Biotherapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapeutic Area
        • 10.3.3.2.2. By Technology

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Next Generation Biotherapeutics Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Xencor, Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (If Listed)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. Regenxbio & Neurimmune AG
  • 14.3. Takeda Pharmaceutical Company Limited
  • 14.4. Pfizer, Inc.
  • 14.5. AstraZeneca Plc.
  • 14.6. F. Hoffmann-La Roche Ltd.
  • 14.7. Kyowa Kirin Co., Ltd
  • 14.8. Seattle Genetics, Inc
  • 14.9. ImmunoGen, Inc
  • 14.10.Ono Pharmaceuticals Co, Ltd

15. Strategic Recommendations

16. About Us & Disclaimer